BRIDGEWATER, N.J. and THE WOODLANDS, Texas, May 22, 2018 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has accepted Sanofi's regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition…Original Article
FDA to Review Zynquista (sotagliflozin) as Potential Treatment for Type 1 Diabetes
